 "Natco Pharma hits record high after launching hepatitis C drug in Nepal")
Shares of Natco Pharma were trading higher by 4% at Rs 1,609, extending its previous day’s 2.5% gain on BSE, after the company announced that it has launched the first generic version of sofosbuvir in Nepal.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®. Natco markets generic sofosbuvir under its brand HEPCINAT, the company said in a press release.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal.
The company said it hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI).
The pharmaceutical company had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries, it added.
The stock opened at Rs 1,583 and hit a high of Rs 1,625, also its record high on BSE. Till 0930 hours, a combined 27,629 shares changed hands on the counter on BSE and NSE.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®. Natco markets generic sofosbuvir under its brand HEPCINAT, the company said in a press release.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal.
The company said it hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI).
The pharmaceutical company had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries, it added.
The stock opened at Rs 1,583 and hit a high of Rs 1,625, also its record high on BSE. Till 0930 hours, a combined 27,629 shares changed hands on the counter on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%